Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 17/20 | 0.59 |
| ▸ | SCTR | P47872 | 1/20 | 0.59 |
| ▸ | GCGR | P47871 | 1/20 | 0.56 |
| ▸ | CALCR | P30988 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30207768 | 0.97 | GLP1R (0.56) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL30320200 | 0.97 | GLP1R (0.56) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL30320225 | 0.97 | GLP1R (0.56) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL29913342 | 0.97 | GLP1R (0.56) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL30320221 | 0.97 | GLP1R (0.56) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL30320255 | 0.96 | GLP1R (0.55) | GLP1RSCTRGCGR | |
| SCHEMBL29367449 | 0.96 | GLP1R (0.58) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL29364498 | 0.96 | GLP1R (0.58) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL29367867 | 0.96 | GLP1R (0.58) | GLP1RSCTRGCGRCALCR | |
| SCHEMBL30637756 | 0.95 | GLP1R (0.57) | GLP1RSCTRF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | PEGBIO CO., LTD. (CN) | 2024-08-22 | — | — | US | claimed |
| WO-2023001186-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | 派格生物医药(苏州)股份有限公司 | 2023-01-26 | — | — | WO | claimed |
| CN-115634285-A | Application of polypeptide conjugate in preparation of medicines for treating diseases related to glycometabolism | 派格生物医药(苏州)股份有限公司 | 2023-01-24 | — | — | CN | claimed |
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | PEGBIO CO., LTD. (CN) | 2024-08-22 | — | — | US | disclosed |
| CN-118512602-A | Compound pharmaceutical composition and application thereof | 派格生物医药(苏州)股份有限公司 | 2024-08-20 | — | — | CN | disclosed |
| US-20230302093-A1 | NASAL POWDER FORMULATION FOR TREATMENT OF HYPOGLYCEMIA | AMPHASTAR PHARMACEUTICALS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2023001186-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | 派格生物医药(苏州)股份有限公司 | 2023-01-26 | — | — | WO | disclosed |
| CN-115634285-A | Application of polypeptide conjugate in preparation of medicines for treating diseases related to glycometabolism | 派格生物医药(苏州)股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277816-A1 | POLYPEPTIDE CONJUGATE AND APPLICATION THEREOF IN PREPARATION OF DRUG FOR TREATING DISEASES RELATED TO GLUCOSE METABOLISM | IAPP, GIPR, GCG | GLP1R 5/4885SCTR 58/4885GCGR 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.